Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate Vaccines.
carrier protein
glycoconjugate
tetanus toxoid
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
20
09
2023
revised:
07
11
2023
accepted:
23
11
2023
medline:
23
12
2023
pubmed:
23
12
2023
entrez:
23
12
2023
Statut:
epublish
Résumé
Glycoconjugate vaccines play a major role in the prevention of infectious diseases worldwide, with significant impact on global health, enabling the polysaccharides to induce immunogenicity in infants and immunological memory. Tetanus toxoid (TT), a chemically detoxified bacterial toxin, is among the few carrier proteins used in licensed glycoconjugate vaccines. The recombinant full-length 8MTT was engineered in
Identifiants
pubmed: 38140177
pii: vaccines11121770
doi: 10.3390/vaccines11121770
pii:
doi:
Types de publication
Journal Article
Langues
eng